The first generic versions of Boniva, the once-a-month medication marketed by Genentech and prescribed to prevent or treat osteoporosis after menopause, has been approved by the FDA. The generic name of the drug is ibandronate, and approval was granted to Apotex, Orchid Healthcare, and Mylan Pharmaceuticals.
Patients who get the new generics will also receive a guide listing possible the adverse side effects including esophageal problems, low blood-calcium levels, unusual thigh bone fractures, back pain, dyspepsia, extremity pain, diarrhea, headache, muscle pain, and myalgia.
CONTRIBUTE TO THIS STORY
